Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
CA125 is the gold standard tumor marker in ovarian cancer. Serum level of CA125 is used to monitor response to chemotherapy, relapse, and disease progression in ovarian cancer patients. Thus, it is reasonable to investigate whether CA125 may have utility as a prognostic indicator as well in ovarian cancer. A large number of epidemiological studies have been carried out to this effect. This review summarizes all available epidemiological literature on the association between CA125 levels and survival in ovarian cancer. To place these studies in context, we provide some background information on CA125 and its role in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
New tumor markers: CA125 and beyond
BAST, R. C., BADGWELL, D., LU, Z., MARQUEZ, R., ROSEN, D., LIU, J., BAGGERLY, K. A., ATKINSON, E. N., SKATES, S., ZHANG, Z., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00441.x · Cited by 504
Eisenkop, S. M., Spirtos, N. M., Friedman, R. L., Lin, W.-C. M., Pisani, A. L., & Perticucci, S. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00278-6 · Cited by 410
CA 125: The past and the Future
Bast, R. C., Xu, F.-J., Yu, Y.-H., Barnhill, S., Zhang, Z., & Mills, G. B. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300402 · Cited by 397
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
DUFFY, M. J., BONFRER, J. M., KULPA, J., RUSTIN, G. J. S., SOLETORMOS, G., TORRE, G. C., TUXEN, M. K., & ZWIRNER, M. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00130.x · Cited by 317
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The subset of cancer-derived molecules (e.g., CA125, Sialyl-Tn and CA19-9) that survive such clearance then become useful markers of disease progression (948) (949) (950) (951) .”
BackgroundParkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer
Asher, V., Lee, J., Innamaa, A., & Bali, A. (2011) · Clinical and Translational Oncology · doi:10.1007/s12094-011-0687-9 · Cited by 238
Hamd-Ghadareh, S., Salimi, A., Fathi, F., & Bahrami, S. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.05.003 · Cited by 214
A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer
Samadi Pakchin, P., Fathi, M., Ghanbari, H., Saber, R., & Omidi, Y. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112029 · Cited by 170
Metadata
- Authors
- Gupta, D., & Lis, C. G.
- Affiliations
- Cancer Treatment Centers of America (US)
- Corresponding author
- Lis, Christopher G
- ORCID
- Gupta, Digant
- Venue
- Journal of Ovarian Research
- Published
- 2009
- Volume
- 2
- Issue
- 1
- Pages
- 13
- ISSN
- 1757-2215 (ISSN-L)
- PMC
- PMC2764643
- OpenAlex
- W2022462471
- Cited by
- 208
- References
- 82
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 20 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 14 · 2016: 19 · 2015: 13 · 2014: 9 · 2013: 11 · 2012: 8
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Ovarian Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- CA125, ovarian cancer, prognostic factors, survival, serum tumor markers, chemotherapy response monitoring, relapse detection, disease progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. https://app.cochat.ai/papers/10.1186/1757-2215-2-13
- The paper
- Gupta, D., & Lis, C. G. (2009). Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. Journal of Ovarian Research. https://doi.org/10.1186/1757-2215-2-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.